Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial - Concepedia

Concepedia

Publication | Open Access

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial

DOI Full Paper Access

203

Citations

28

References

2020

Year

Chunyan Lan, JingXian Shen, Yin Wang, Jundong Li, Zhimin Liu, Mian He, Xinping Cao, Jiayu Ling, Jiaming Huang, Min Zheng,

Journal of Clinical Oncology

Abstract

Camrelizumab plus apatinib had promising antitumor activity and manageable toxicities in patients with advanced cervical cancer. Larger randomized controlled trials are warranted to validate our findings.

References

	Year	Citations

Page 1